News for REPCF Stock
RepliCel Provides Corporate Update
RepliCel Announces Material Patent Milestones in Key Markets
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
RepliCel’s Manufacturing Inspected by Japan’s PMDA
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
RepliCel Announces Material Patent Milestones
RepliCel Closed Final Tranche of Strategic Investment Commitment
RepliCel Terminates License Agreement with Shiseido
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
RepliCel Announces Dermal Injector Update
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
RepliCel Adds Independent Director
RepliCel Launches Testing of Dermal Injector Units
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
RepliCel Announces Record Year in Patents Granted
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
RepliCel Closes Second Tranche of Strategic Investment Commitment
RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
RepliCel Closes First Tranche of Strategic Investment Commitment
RepliCel CEO Provides Corporate Update
Back to Sitemap